Effect of anamorelin, a ghrelin receptor agonist, on muscle and bone in adults with osteosarcopenia.

Bess Dawson-HughesKathryn BargerElise ReitshamerRoger A FieldingWilliam EvansLisa Ceglia

Published in: The Journal of clinical endocrinology and metabolism (2023)

In this pilot study, anamorelin did not significantly alter muscle mass; however, it may potentially improve lower extremity strength and bone formation in addition to increasing circulating IGF-1 levels in adults with osteosarcopenia. Further study of anamorelin in this population is warranted.

Keyphrases

skeletal muscle
bone mineral density
growth hormone
binding protein
cell proliferation